Weakness in shares of T2 Biosystems is being attributed to a short report published earlier on Seeking Alpha by White Diamond Research. In the report, White Diamond claims that T2’s system “is becoming a commercial flop like other bacteremia (bacteria in the blood) testing diagnostic systems before it.” The research firm, which set a $1.50 price target on T2 Biosystems shares, added that “in every 2018 quarter, TTOO’s unsustainable research revenue was higher than its much more important product revenue.” In afternoon trading, T2 shares are down 59c, or 14%, to $3.70
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.